Thyrocare Technologies: An Analysis
Thyrocare Technologies is a small healthcare company that recently announced a bonus share issue. This means investors get extra shares for each one they own. Because of this, the stock price is changing, and it’s important to understand how it’s performing. Let’s break down what’s happening with the company’s stock.
Key Points
- Stock gained 0.3% on Wednesday due to bonus issue.
- Bonus issue: 2 new shares for every 1 owned.
- Stock is up 138% this year, 303% since FY25 started.
- Paid two dividends in 2025 (₹21 & ₹7 per share).
- Public shareholders own 29%, promoters own 71%.
- Q2 net profit grew 81.6%, sales up 22.1%.
The company announced a 2:1 bonus share issue, meaning shareholders will receive two bonus shares for every one share they already hold. This usually makes the stock more affordable and can increase demand. Currently, the stock price is significantly higher than its lowest point over the past year – up 128%. However, it’s still down slightly from its highest point – 7%.
Despite the recent gains, the stock has had a rough past week, losing almost 4%. But, over the last two months, it’s soared by nearly 40%, and a massive 138% so far this financial year (FY26). This impressive growth demonstrates strong investor confidence.
Thyrocare Technologies has paid out dividends twice in 2025. The company declared a final dividend of ₹21 per share in July and an interim dividend of ₹7 per share in October. The company’s shareholding shows that promoters control 71.06% of the stock, while public shareholders own 28.94%.
In its latest quarterly results, Thyrocare Technologies reported an 81.6% jump in consolidated net profit to ₹47.90 crore for the quarter ended September 2025, compared to ₹26.37 crore a year ago. Total sales increased by 22.1% year-on-year to ₹216.53 crore in Q2FY26.
Technical analysis suggests the stock is looking good. It’s trading above key moving averages and the price action indicates a positive trend. The stock price is likely to remain positive as long as it sustains above ₹1,334 (super trend line).
Takeaway: Investing in Thyrocare Technologies offers potential for significant growth but involves assessing the company’s performance and future prospects carefully.
